RE: RNS22 Aug 2024 09:43
Commenting Paul Pagano, Chief Executive Officer of LungLife, said:
"The successful clinical validation of the LungLB® test and other achievements in this period reflect our commitment to advancing early detection of lung cancer and the team remains dedicated to making a significant impact in this critical area of healthcare.
We are delighted with the increasing recognition for LungLB® as evidenced by the positive clinician feedback together with the first orders being received under our Early Access Program. Whilst we progress towards commercialisation, we are also actively seeking opportunities for a suitable strategic partner who aligns with our vision and has the capability to accelerate the adoption of LungLB®."